Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.
about
Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic painClinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic reviewUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceCurrent and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Toward a systematic approach to opioid rotation.Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliationBuprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewNerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatmentNegotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study.Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected PatientsInteractions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsMaintenance medication for opiate addiction: the foundation of recovery.Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findingsTreating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.Receipt of opioid analgesics by HIV-infected and uninfected patientsDo drug treatment variables predict cognitive performance in multidrug-treated opioid-dependent patients? A regression analysis study.Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.The next therapeutic challenge in HIV: polypharmacy.Lack of clinically significant drug interactions between nevirapine and buprenorphine.CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.Role of cytochrome P4502B6 in methadone metabolism and clearance.Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIVCytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Selective review and commentary on emerging pharmacotherapies for opioid addiction.A service improvement project to review prescribing information provided by general practitioners for new referrals to a UK National Health Service hospital pain clinic: potential implications of CYP2D6 enzyme inhibition.Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.Chronic and acute pain and pain management for patients in methadone maintenance treatment.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.Pharmacotherapies for treating opioid use disorder.Economic implications of potential drug-drug interactions in chronic pain patients.
P2860
Q26775658-F326A98D-C975-4576-BD4E-53495941C3D0Q26781972-F74AB35C-1996-4E89-A2C4-4EC824564E82Q26865674-F22C9B1C-C5DC-48EA-ADE1-4044734D76BAQ27692554-9D2A7AD6-F9BD-4215-93A2-A480C96CF26EQ33688813-BDFF3461-B110-48B0-911A-25D665A5B7ECQ33870389-6817B4E5-59D9-446E-904B-EF8B21C97603Q34394425-979F4693-A166-4917-8544-07EBC76D2EA7Q34424648-6FB614DB-8326-4DF7-9E69-BBC40A2E960DQ34615753-A15AF85D-5671-4709-9B19-1318BA51F1AAQ35084340-1F4E0D64-AE2F-45B5-A412-DB1026504A2DQ35087543-4BF94DAC-9866-4852-93B7-222572CA9B01Q35581138-9C3F4A95-36B4-48FA-96B1-95D3203328E2Q35657944-AEF34629-10ED-497E-9DCB-BF1719C10A4BQ35672530-086C64CD-DED6-4FB0-A087-1B2B9AE5E929Q35738851-6249344C-6D71-4D26-8927-57C3C0740504Q35738885-1C6A6373-DA11-42A7-91D7-802CB878D0D9Q36138164-02EB0E43-11E5-4D60-B61D-AC40FCBEF134Q36263653-C85C5AFD-9EF9-4C5A-9193-3398B23C3256Q36367544-4AC6DD54-7F6B-414C-BDA0-BC899FE784F6Q36514613-4EB1C166-3013-48DB-BF22-51FC40D1239AQ36552459-67B980B7-4948-471F-BBB6-5F054AC9E033Q36619578-5BF5A568-60E2-4C0D-A364-C161C48A17C5Q36652680-45C43861-3432-4D4E-BDB3-7985A06A8024Q36717150-1663EC16-4D22-48D7-9CFE-AD44AE54E089Q37025385-D33398DE-889B-4509-97D4-1B4AFE7D46D6Q37045349-8109A902-DA2A-4DED-A909-46C9A933CF64Q37075089-13E8C3F4-B557-4E07-BF22-C8E8EA375E36Q37094439-40148388-3387-4A33-B653-31D4BBC13C10Q37117193-48F1242C-F017-4694-8F03-0995E7293CC2Q37222229-1023A3AC-52FC-4060-B521-BE737E202FBAQ37325606-648B6747-0AAD-4BA3-8435-14BBC4E31F55Q37355286-422F3A10-8463-4FBD-BFE5-D2E8AC9DCC73Q37403673-3F6678C9-4621-4CDA-AA98-F7CC6C706E90Q37409042-49B56235-33F1-4A6B-838E-71D866ED057DQ37549796-C3B5C3EA-C16A-4528-A0C3-795423A90859Q37705253-73B751FF-3B57-4E8D-8E75-4FEF515FBF0DQ38080567-9DC6A7DE-2FE1-44DE-862B-60DFF07EE794Q38093852-F8C1DE0D-2A0C-4DFC-A444-A81919FED198Q38096571-FEDD1586-EE58-4675-BDDF-2318A3DAA64FQ38161917-3491DCDC-EDEA-4539-A659-11A209D7C4C3
P2860
Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Drug interactions of clinical ...... scribed medications: a review.
@ast
Drug interactions of clinical ...... scribed medications: a review.
@en
type
label
Drug interactions of clinical ...... scribed medications: a review.
@ast
Drug interactions of clinical ...... scribed medications: a review.
@en
prefLabel
Drug interactions of clinical ...... scribed medications: a review.
@ast
Drug interactions of clinical ...... scribed medications: a review.
@en
P2093
P2860
P1476
Drug interactions of clinical ...... scribed medications: a review.
@en
P2093
Elinore F McCance-Katz
Lynn E Sullivan
Srikanth Nallani
P2860
P356
10.1111/J.1521-0391.2009.00005.X
P577
2010-01-01T00:00:00Z